10-K: SCYNEXIS Shifts Focus to SCY-247 After MARIO Study Termination

Sentiment:

Annual Report 4 March 2026 4:01 PM

SCYNEXIS, Inc. reported a net loss of $8.6 million for FY2025, terminated the MARIO study with GSK for a $24.8 million payment, and is advancing its second-generation antifungal SCY-247 into Phase 1 IV and Phase 2 oral trials.

Delay expectedThe MARIO study for ibrexafungerp, which had resumed in April 2025 after an FDA clinical hold was lifted, was subsequently terminated by GSK in October 2025. This represents a delay and ultimate cessation of a significant clinical development program for ibrexafungerp in the IC indication.GSK anticipates initiating regulatory interactions with the FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market, indicating a delay in the commercialization timeline for this product.

Capital raiseThe company expects to continue to incur significant expenses and operating losses for the foreseeable future and will require substantial additional capital to fund operations.Additional funding may be obtained through equity offerings, debt financings, or other non-dilutive third-party funding, strategic alliances, and licensing or collaboration arrangements.On November 6, 2024, the company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. to sell up to $50.0 million of common stock through an at-the-market offering program, though zero shares were sold as of December 31, 2025.The company may need to grant additional stock options, amend existing option awards, or provide alternative compensation to retain key personnel, which could impact equity.The Nasdaq minimum bid price non-compliance may necessitate a reverse stock split, which is a form of capital restructuring.

Better than expectedNet loss significantly decreased to $8.6 million in 2025 from $21.3 million in 2024, indicating improved financial performance.Total revenue increased substantially to $20.6 million in 2025 from $3.7 million in 2024, primarily due to a $17.2 million cumulative catch-up from the GSK license agreement.Received a $24.8 million one-time, non-refundable payment from GSK, providing a significant cash infusion.Positive Phase 1 results for oral SCY-247, demonstrating good safety, tolerability, and achieving target efficacious exposure, supporting continued clinical development.Initiation of Phase 1 IV study and planned Phase 2 oral study for SCY-247 in 2026 shows progress in the pipeline.

Summary

Net loss significantly decreased to $8.6 million for the year ended December 31, 2025, compared to $21.3 million in 2024.
Total revenue increased to $20.6 million in 2025 from $3.7 million in 2024, primarily driven by a $17.2 million cumulative catch-up of license agreement revenue from GSK.
Received a one-time, non-refundable payment of $24.8 million from GSK in November 2025 following the termination of the MARIO study for ibrexafungerp.
Research and development expenses decreased by 15.6% to $22.3 million in 2025, mainly due to reduced chemistry, manufacturing, and controls (CMC) expense and lower salary/stock-based compensation.
SCY-247, a second-generation fungerp, showed positive safety, tolerability, and pharmacokinetic results in a Phase 1 oral study in 88 healthy subjects, achieving target efficacious exposure for invasive candidiasis.
Initiated a Phase 1 study for the intravenous formulation of SCY-247 in Q1 2026 and plans a clinical proof-of-concept Phase 2 study for SCY-247 in invasive candidiasis (IC) in 2026.
GSK is committed to commercializing BREXAFEMME for VVC and rVVC and anticipates initiating regulatory interactions with the FDA in 2026 for its relaunch in the U.S. market.
Accumulated deficit was $385.1 million as of December 31, 2025, with cash, cash equivalents, and investments totaling $56.3 million.
Received a Nasdaq notification for failing to meet the $1.00 minimum bid price requirement, with an extension until June 15, 2026, to regain compliance, potentially through a reverse stock split.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While the company continues to incur losses and faces Nasdaq compliance issues, the significant reduction in net loss, the cash infusion from GSK, and the promising advancement of SCY-247 into later-stage clinical trials provide a clear path forward and mitigate some financial risks.

Positives

Net loss significantly reduced to $8.6 million in 2025 from $21.3 million in 2024.
Total revenue increased substantially to $20.6 million in 2025, driven by a $17.2 million cumulative catch-up from the GSK license agreement.
Received a $24.8 million one-time, non-refundable payment from GSK related to the MARIO study termination.
SCY-247 oral formulation demonstrated good safety, tolerability, and dose-proportional pharmacokinetics in Phase 1, achieving target efficacious exposure for invasive candidiasis.
SCY-247 has Qualified Infectious Disease Product (QIDP) status and Fast Track designation, potentially offering expedited review and 10 years of regulatory exclusivity if approved.
Initiated Phase 1 study for intravenous SCY-247 in Q1 2026 and plans Phase 2 study in IC for 2026, indicating continued pipeline progression.
GSK reiterated commitment to commercializing BREXAFEMME for VVC and rVVC, with anticipated regulatory interactions for relaunch in 2026.
SCY-247 shows potent activity against multidrug-resistant fungal pathogens, including Candida auris and echinocandin-resistant Candida glabrata, addressing significant unmet medical needs.
SCY-247's unique attributes include oral bioavailability, fungicidal capabilities against Candida, high tissue penetration, and low risk of drug-drug interactions.

Negatives

Continued net losses, with an accumulated deficit of $385.1 million as of December 31, 2025.
Termination of the MARIO study for ibrexafungerp by GSK, resulting in no further development milestone payments specifically for this study.
Nasdaq minimum bid price non-compliance, requiring the company to regain compliance by June 15, 2026, potentially through a reverse stock split, which can be dilutive or negatively perceived.
Cash, cash equivalents, and investments decreased to $56.3 million as of December 31, 2025, from $75.1 million as of December 31, 2024.
Will continue to require substantial additional capital to fund operations and development programs, with no guarantee of availability on acceptable terms.
Limited history of profitability and only one product (ibrexafungerp) approved for commercial sale, which is licensed to GSK.
Product revenue, net, for 2025 included a $1.4 million change in estimate related to a prior period product recall of BREXAFEMME.

Risks

Limited profitability and need for additional capital: A limited history of profitability, only one product approved for commercial sale (licensed to GSK), and limited revenue from product sales. Expects to incur significant expenses and operating losses for the foreseeable future and will require substantial additional capital. Inability to raise capital when needed would force delays, reductions, or elimination of the SCY-247 development program.
Regulatory approval uncertainty for SCY-247: Cannot be certain that SCY-247 will receive regulatory approval in the indications being pursued. Regulatory approval is a lengthy, expensive, and uncertain process, and QIDP and Fast Track designations do not guarantee approval or significantly shorter review times.
Clinical trial delays and failures: Delays in commencement, enrollment, and completion of clinical trials could increase costs and delay or limit regulatory approval. Clinical failure can occur at any stage, and earlier trial results are not necessarily predictive of future results.
Market acceptance and competition: If SCY-247 does not achieve broad market acceptance, revenue will be limited. Expects to face competition from companies with significantly greater resources, and competitors may develop safer, more effective, or less expensive products.
Antifungal resistance: If resistance to SCY-247 develops quickly or cross-resistance with echinocandins becomes more common, the business will be harmed.
Undesirable side effects: SCY-247 may have undesirable side effects that could delay or prevent marketing approval, or, if approval is received, require them to be taken off the market or otherwise limit their sales.
Reimbursement challenges: Reimbursement decisions by third-party payors may adversely affect pricing and market acceptance. Insufficient reimbursement makes it less likely products will be purchased.
Dependence on third-party collaborations: Dependent on license agreements with GSK, Hansoh, and R-Pharm for commercialization of ibrexafungerp. If these partners are unsuccessful, SCYNEXIS will lose significant potential revenue.
Dependence on third-party contractors: Relies on third-party contractors for a substantial portion of drug development activities and manufacturing, which introduces risks related to performance, timeliness, and regulatory compliance.
Intellectual property protection: Difficult and costly to protect proprietary rights. Patents may be challenged, deemed invalid, or not provide sufficient competitive advantage. Litigation related to intellectual property is expensive and time-consuming.
Management and growth challenges: Inability to attract and retain key personnel or effectively manage growth as operations expand could adversely affect the business.
Product liability exposure: Use of product candidates in clinical trials and sale of approved products expose the company to product liability claims, which could result in substantial liabilities not fully covered by insurance.
Cybersecurity threats and data privacy: Vulnerability of internal computer systems and those of contractors to damage, data leakage, and security breaches. Non-compliance with evolving data privacy and security laws (e.g., CCPA, GDPR) could lead to investigations, fines, litigation, and reputational harm.
Market price volatility and dilution: The market price of common stock may be highly volatile. Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
Anti-takeover provisions: Charter documents and Delaware law provisions could make an acquisition more difficult and prevent attempts by stockholders to replace management.
Nasdaq delisting risk: Failure to comply with Nasdaq's minimum bid price requirement could lead to delisting, negatively impacting stock price and access to capital markets.
Tax law changes: Uncertainties in the interpretation and application of existing, new, and proposed tax laws (e.g., OBBBA, Tax Cuts and Jobs Act) could materially affect tax obligations and effective tax rate, including limitations on net operating loss carryforwards.

Future Outlook

SCYNEXIS intends to progress the development of SCY-247 to address significant unmet needs in the antifungal space, representing attractive commercial opportunities. A Phase 1 study with the intravenous formulation of SCY-247 was initiated in Q1 2026, and a clinical proof-of-concept Phase 2 study in patients with invasive candidiasis (IC) is planned for 2026. Subsequent development stages for SCY-247 are anticipated to include studies supporting an IC treatment indication and evaluation for prevention of invasive fungal infections (IFI) in high-risk patients. GSK anticipates initiating regulatory interactions with the FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market. The company will continue to require substantial additional funding to support its operations and development strategy.

Management Comments

"We remain committed to developing novel antifungal solutions to the rising threat of deadly fungal infections including IC for which there are limited treatment options and significant concerns for emergence of resistances, as highlighted by the World Health Organization in their call to industry and other parties for research, development and public health action in this area of unmet need."
"We believe that SCY-247, if approved, has the potential to address significant gaps with commercially available therapies in the following indications: IC, including resistant infections, and prevention of IFI in patients at high risk."
"We believe that the fungerps have the ability to perform well in the future fungal infection market given the limited competitive marketplace, the unmet medical need, and the often high mortality rate of many of these infections."
"We believe that the fungerp's unique features, including being from a novel antifungal class, broad-spectrum of activity including resistant strains, intravenous and oral formulations, fungicidal activity versus Candida, high tissue penetration, and favorable safety profile, will differentiate it from competing products and allow premium pricing to generics and other competing products."

Industry Context

StockSavvy.ai notes that SCYNEXIS operates in a highly competitive pharmaceutical industry, particularly within the antifungal market, which faces increasing challenges from drug-resistant pathogens like Candida auris and echinocandin-resistant Candida glabrata. The company's focus on developing novel fungerps, a distinct class of antifungals, positions it to address critical unmet needs, especially given the high mortality rates associated with invasive fungal infections and the limitations of existing therapies (echinocandins, azoles, amphotericin B). The termination of the MARIO study for ibrexafungerp, while providing a cash infusion, underscores the inherent risks and strategic shifts common in drug development, allowing SCYNEXIS to concentrate resources on its promising second-generation candidate, SCY-247. The broader industry trend of increasing regulatory scrutiny on drug safety and pricing, as well as the impact of healthcare reform initiatives like the Inflation Reduction Act, will continue to shape the commercial landscape for new pharmaceutical products.

Comparison to Industry Standards

SCYNEXIS's SCY-247, a second-generation fungerp, is being developed to address limitations of current antifungal drug classes: echinocandins (e.g., Rezzayo by Melinta Therapeutics, Cancidas by Merck, Mycamine by Astellas, Eraxis by Pfizer), azoles (e.g., Noxafil by Merck, Cresemba by Astellas, Vivjoa by Mycovia Pharmaceuticals, Diflucan by Pfizer), and polyenes (e.g., AmBisome by Gilead/Astellas/Dainippon-Sumitomo).
SCY-247 aims to differentiate itself with oral bioavailability for outpatient use, activity against azole-resistant and most echinocandin-resistant Candida strains (including Candida auris and multidrug-resistant strains), activity against azole-resistant Aspergillus strains, fungicidal capabilities against Candida (unlike fungistatic azoles), high tissue penetration, and a low risk of drug-drug interactions.
Current treatment options for Invasive Candidiasis (IC) are limited, with echinocandins as first-line but only available intravenously, and oral azoles used as step-down agents but facing rising resistance. Amphotericin B, also IV-only, carries significant renal toxicity risks. SCY-247's oral and IV formulations, broad-spectrum activity, and favorable safety profile aim to overcome these limitations.
Competitors also have drugs in development, such as Fosmanogepix (Basilea Pharmaceuticals Inc.), MAT2203 (Matinas BioPharma Holdings Inc.), and Olorofim (F2G Limited), indicating an active R&D landscape for novel antifungals.
The company believes SCY-247's unique features will allow premium pricing over generic competitors like fluconazole, itraconazole, posaconazole, oral voriconazole, and caspofungin.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Cybersecurity Risk Oversight	The board of directors, through its Audit Committee, is responsible for overseeing the company's cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats. The Audit Committee receives periodic reports from company management concerning significant cybersecurity threats and risks.	NA	Enhances corporate oversight of critical cybersecurity risks, aligning with evolving regulatory expectations and best practices.
Equity Incentive Plan Adoption	The 2024 Equity Incentive Plan was adopted by the board of directors and approved by stockholders, replacing the 2014 Equity Incentive Plan. The 2014 Plan terminated on February 11, 2024, with no new grants allowed.	2024-06-19	Provides a new framework for equity compensation, crucial for attracting and retaining talent, aligning employee incentives with shareholder interests.
Inducement Plan Share Reserve Increase	The 2015 Inducement Plan's initial share reserve was increased multiple times, from 45,000 to 90,000, then to 500,000, and finally to 900,000 shares of common stock.	2019-06-09, 2021-04-30, 2022-10-18	Expands the company's ability to grant equity awards as inducements for new employees, supporting growth and talent acquisition.
Non-Employee Director Compensation Policy	Non-employee directors receive an annual base cash retainer of $45,000, with the chairman receiving an additional $35,000. Committee chairpersons and members also receive annual cash retainers. Annual equity grants include 23,000 RSUs and 23,000 stock options, vesting over one year. New board members receive initial grants of 46,000 RSUs and 46,000 stock options, vesting over three years. Directors may elect to receive nonstatutory stock options in lieu of cash compensation.	NA	Aims to attract and retain qualified independent directors by providing competitive compensation, including equity incentives, aligning their interests with long-term company performance.

Legal Proceedings

A securities class action filed on November 7, 2023, by Brian Feldman against the company and certain executives, alleging misstatements regarding manufacturing controls, was dismissed with prejudice on August 29, 2025.
Purported shareholder derivative complaints filed on May 1, 2024, and June 4, 2024, asserting related claims, were consolidated and later dismissed without prejudice on October 15, 2025.

Related Party Transactions

The Senior Convertible Note Purchase Agreement with Puissance Life Science Opportunities Fund VI (Puissance), entered into on March 7, 2019, involved the issuance and sale of $16.0 million aggregate principal amount of 6.0% Senior Convertible Notes due 2025. Puissance converted $2.0 million of these notes into 162,600 shares of common stock in April 2019. The remaining $14.0 million was repaid at maturity on March 15, 2025.

Stakeholder Impact

Shareholders: Potential for dilution from future equity offerings; risk of delisting from Nasdaq if minimum bid price is not met; potential for increased value if SCY-247 development is successful; impact from the termination of the MARIO study and the $24.8 million payment from GSK.
Employees: Stock-based awards are critical for retention, but low stock price may reduce their value; potential for increased headcount as SCY-247 advances; impact of management's ability to attract and retain key personnel.
Customers/Patients: Potential for new treatment options for severe fungal infections with SCY-247; continued availability of BREXAFEMME through GSK's commercialization efforts.
Partners (GSK, Hansoh, R-Pharm): GSK's termination of the MARIO study impacts the collaboration scope but reiterates commitment to BREXAFEMME commercialization; Hansoh and R-Pharm's success in their respective territories is crucial for SCYNEXIS's royalty revenue.
Creditors: Repayment of $14.0 million convertible debt in March 2025 reduces debt obligations.

Next Steps

Complete the ongoing Phase 1 study with the intravenous formulation of SCY-247 in 2026.
Initiate a Phase 2 clinical proof-of-concept study of SCY-247 in patients with Invasive Candidiasis (IC) in 2026.
Conduct subsequent stages of development for SCY-247 to support an IC treatment indication and evaluate it for prevention of invasive fungal infections (IFI) in high-risk patients.
GSK anticipates initiating regulatory interactions with the FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market.
Explore potential non-dilutive funding opportunities to further support SCY-247 development.
Assess external opportunities for in-licensing to expand the development pipeline and add products for commercialization.
Regain compliance with Nasdaq's minimum bid price requirement by June 15, 2026, potentially through a reverse stock split.

Key Dates

Date	Description
1999-11-04	Incorporated in the State of Delaware.
2013-05-01	Entered into a license arrangement with Merck Sharp & Dohme Corp. for ibrexafungerp.
2014-01-01	Merck assigned patents related to ibrexafungerp to SCYNEXIS.
2014-02-01	SCYNEXIS's board of directors adopted the 2014 Employee Stock Purchase Plan (2014 ESPP).
2014-05-02	2014 ESPP became effective.
2014-05-07	Amended and restated articles of incorporation relating to approved capital structure.
2014-10-01	Entered into a license agreement with Waterstone Pharmaceutical HK Limited.
2014-12-03	Entered into an amendment to the license agreement with Merck, deferring a milestone payment.
2015-03-26	SCYNEXIS's board of directors adopted the 2015 Inducement Plan.
2016-07-01	Entered into an asset purchase agreement with Cypralis Limited for the sale of its cyclophilin inhibitor assets.
2016-12-01	Entered into a second amendment to the license agreement with Merck.
2018-01-01	Entered into a third amendment to the license agreement with Merck.
2018-03-01	Entered into a long-term lease agreement for office space in Jersey City, New Jersey.
2018-08-01	Lease commencement date for office space.
2019-01-01	Milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program.
2019-03-01	Paid milestone payment to Merck.
2019-03-07	Entered into a Senior Convertible Note Purchase Agreement with Puissance Life Science Opportunities Fund VI.
2019-04-01	Puissance converted $2.0 million of March 2019 Notes for 162,600 shares of common stock.
2019-07-01	Incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia.
2020-12-02	Entered into a fourth amendment to the license agreement with Merck, eliminating two cash milestone payments.
2021-02-11	Entered into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Limited.
2021-06-01	FDA approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC).
2021-11-01	Entered into a consulting agreement with Danforth Advisors, issuing a warrant to purchase 50,000 shares.
2022-01-01	FDA approved BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
2022-04-22	Entered into an Equity Underwriting Agreement for a public offering of common stock and warrants.
2023-03-30	Entered into an exclusive license agreement with GlaxoSmithKline Intellectual Property (No.3) Limited (GSK).
2023-05-01	Closed transactions contemplated by the GSK License Agreement.
2023-06-14	Amended 2014 ESPP ratified by stockholders and became effective.
2023-12-22	Entered into a binding memorandum of understanding (Binding 2023 MOU) with GSK to amend the GSK License Agreement.
2024-01-01	CPRA (California Privacy Rights Act of 2020) became effective.
2024-02-11	2014 Equity Incentive Plan terminated, no new grants may be made.
2024-04-01	SCYNEXIS's board of directors adopted the 2024 Equity Incentive Plan.
2024-05-01	Purported shareholder derivative complaints asserting related claims filed in the United States District Court, District of New Jersey.
2024-06-04	Purported shareholder derivative complaints asserting related claims filed in the United States District Court, District of New Jersey (later consolidated).
2024-06-19	2024 Equity Incentive Plan became effective after stockholder approval.
2024-08-15	HHS announced agreed-upon prices of the first ten drugs subject to Medicare Drug Price Negotiation Program.
2024-11-06	Entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. for up to $50.0 million of common stock.
2024-12-07	Initiative to control prescription drug prices through march-in rights under the Bayh-Dole Act announced.
2024-12-08	National Institute of Standards and Technology published Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.
2025-01-05	FDA approved Florida's Section 804 Importation Program (SIP) proposal.
2025-01-17	HHS selected fifteen additional products covered under Part D for price negotiation in 2025.
2025-03-01	44,663,832 shares of common stock outstanding.
2025-03-15	March 2019 Notes matured and $14.0 million repaid to Puissance.
2025-04-01	MARIO study resumed after FDA lifted clinical hold of ibrexafungerp.
2025-06-20	Received Nasdaq notification for failing to meet the $1.00 minimum bid price requirement.
2025-06-30	Aggregate market value of voting and non-voting common equity held by non-affiliates was $25,650,308.
2025-07-30	Court granted motion to dismiss securities class action with leave to amend.
2025-08-29	Parties stipulated to dismissal, and court dismissed securities class action with prejudice.
2025-10-14	Entered into a binding memorandum of understanding (Binding 2025 MOU) with GSK to wind-down and terminate the MARIO study.
2025-10-15	Court dismissed related consolidated shareholder derivative action without prejudice.
2025-11-01	Received one-time, non-refundable payments totaling $24.8 million from GSK.
2025-11-01	Completed transfer of BREXAFEMME NDA to GSK.
2025-12-01	Received an additional 180-calendar-day extension from Nasdaq to regain minimum bid price compliance.
2026-01-01	Initiated a Phase 1 study with the intravenous formulation of SCY-247.
2026-01-01	GSK anticipates initiating regulatory interactions with the FDA to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market.
2026-01-01	Clinical proof-of-concept Phase 2 study of SCY-247 in patients with IC is currently planned.
2026-03-01	18 employees.
2026-03-03	Date of signing of the 10-K by CEO and CFO.
2026-03-04	Date of Independent Registered Public Accounting Firm's report.
2026-06-15	New deadline to regain Nasdaq minimum bid price compliance.
2027-01-01	Federal research and development credit carryforwards began to expire.
2029-07-01	Lease term for office space ends.
2029-01-01	SCY-247 composition of matter patent (U.S. Patent No. 7,863,465) set to expire.
2032-01-01	Aggregate reductions to Medicare payments to providers of 2% per fiscal year will stay in effect until this date unless additional Congressional action is taken.
2035-01-01	Ibrexafungerp composition of matter patent (U.S. Patent No. 8,188,085) set to expire following patent term extension.
2035-01-01	Three patents covering the citrate salt of ibrexafungerp expire.
2038-01-01	Two patents covering uses of ibrexafungerp expire.
2040-01-01	New patent families for ibrexafungerp formulations or uses could extend protection up to this date if granted.

Recommendation

hold

SCYNEXIS shows improved financial metrics with a reduced net loss and a significant cash infusion from GSK, which provides liquidity. The advancement of SCY-247, a promising second-generation antifungal, into Phase 1 IV and planned Phase 2 trials is a positive development addressing unmet medical needs. However, the company still faces substantial capital requirements, the inherent high risks of drug development, and the ongoing Nasdaq minimum bid price compliance issue, which could lead to a reverse stock split. The termination of the MARIO study, while financially compensated, represents a setback for ibrexafungerp's broader indications. Given the mixed signals of progress and persistent risks, a "hold" recommendation is appropriate for investors to monitor SCY-247's clinical progress and the resolution of the Nasdaq listing issue.

Keywords

Antifungal, SCY-247, Fungerps, Invasive Candidiasis, Drug-resistant infections, Biotechnology, Clinical trials, Pharmaceutical development, SEC filing, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.